HAVCR2 and neoplasm: Several preclinical studies have demonstrated that targeting LAG-3, TIM-3, or TIGIT restores T cell function and inhibits tumor progression, and most studies indicated that coinhibition of different ICPs may effectively enhance antitumor activity.